10-K: AnaptysBio Reports Positive Phase 2b Rosnilimab Results, Advances Immunology Pipeline

AnaptysBio achieved key clinical milestones with its lead drug candidate, rosnilimab, and continues to advance its portfolio of immunology therapeutics.

Summary

• AnaptysBio is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases.
• The company's lead program, rosnilimab, is in Phase 2b trials for rheumatoid arthritis and Phase 2 trials for ulcerative colitis.
• Rosnilimab achieved its primary endpoint in the Phase 2b rheumatoid arthritis trial, showing a statistically significant change in the DAS28-CRP score at Week 12.
• Key secondary endpoints, including ACR20, ACR50, and CDAI LDA scores, also showed positive results.
• The company is also developing ANB033 (Phase 1) and ANB101 (entering Phase 1) for other inflammatory conditions.
• AnaptysBio has a financial collaboration with GSK, generating revenue from milestones and royalties on drugs like Jemperli (dostarlimab).
• GSK reported $598.0 million in Jemperli sales for the year ended December 31, 2024, a greater than 200% increase from 2023.
• On January 31, 2025, AnaptysBio entered into an Exclusive License Agreement with Vanda Pharmaceuticals Inc. (Vanda) for imsidolimab.
• Under the agreement with Vanda, AnaptysBio will receive an upfront payment of $10.0 million, a $5.0 million payment for existing drug supply, and is eligible for up to $35.0 million in future milestones and a 10% royalty on net sales.

Sentiment

Score: 7

Explanation: The positive Phase 2b results for rosnilimab and the continued progress of the pipeline, combined with the revenue from the GSK collaboration, contribute to a positive outlook. However, the company's history of losses and the need for future funding temper the sentiment.

Positives

• Rosnilimab demonstrated positive Phase 2b results in rheumatoid arthritis, achieving the primary endpoint and key secondary endpoints.
• Rosnilimab has a favorable safety and tolerability profile based on Phase 2b data.
• The company has a diverse pipeline of immune cell modulating antibodies with potential applications in various autoimmune and inflammatory diseases.
• The collaboration with GSK provides ongoing revenue and potential for future milestones and royalties.
• The agreement with Vanda provides immediate and potential future revenue.

Negatives

• AnaptysBio has a history of operational losses and may not achieve profitability.
• The company will require additional capital to finance operations, which may not be available on acceptable terms.
• The company is heavily reliant on third-party manufacturers, which introduces risks related to production and supply.
• The biotechnology industry is highly competitive, and AnaptysBio faces competition from companies with greater resources.

Risks

• Clinical trials may fail or be delayed, impacting the commercial viability of product candidates.
• Regulatory approvals may not be obtained or may be delayed.
• Product candidates may not achieve market acceptance.
• The company may not be able to secure additional funding.
• Intellectual property rights may be challenged or invalidated.
• The macroeconomic and geopolitical environment could negatively impact the company's business and operations.

Future Outlook

AnaptysBio anticipates reporting top-line data on the primary endpoint at Week 12 in the UC trial in the fourth quarter of 2025 and plans to initiate enrollment for a Phase 1 clinical trial for ANB101 in the first quarter of 2025. GSK expects top-line results from the Phase 3 COSTAR Lung trial in the first half of 2025.

Industry Context

AnaptysBio is operating in the competitive immunology therapeutics market, focusing on autoimmune and inflammatory diseases. The company's approach of targeting specific immune cell pathways differentiates it from some competitors, but it faces competition from larger pharmaceutical companies and other biotechnology firms developing similar treatments.

Comparison to Industry Standards

• For the PD-1 agonist antibody program, competitors include GS-0151 (Gilead) in Phase 1b development for rheumatoid arthritis, and a PD-1 agonist antibody (Boehringer Ingelheim) in Phase 1 development.
• Commercial-stage competitors in moderate-to-severe rheumatoid arthritis include monoclonal antibodies targeting anti-TNF (Humira; Abbvie), IL-6 (Actemra; Roche and Kevzara; Regeneron), CD-80/86 (Orencia; BMS), CD-20 (Rituxan; Roche), and janus kinase inhibitors (Rinvoq; AbbVie, Olumiant; Eli Lilly, and Xeljanz; Pfizer).
• Commercial-stage competitors in moderate-to-severe ulcerative colitis include monoclonal antibodies targeting anti-TNF (Humira; Abbvie and Remicade; Johnson & Johnson), anti-47 (Entyvio; Takeda), anti-IL-23 (Stelara; Johnson & Johnson, Omvoh; Eli Lilly, Tremfya; Johnson and Johnson, and Skyrizi; AbbVie) and S1P inhibitors (Zeposia; Bristol Myers Squibb and Velsipity; Pfizer) and janus kinase inhibitors (Rinvoq; AbbVie, and Xeljanz; Pfizer) as well as monoclonal antibodies targeting anti-TL1A (PRA023; Merck, RVT-3101; Roche and duvakitug; Teva/Sanofi) in Phase 2 and 3 development.
• For the anti-CD122 antagonist antibody program, clinical competitors include other anti-CD122 antagonist antibodies, auremolimab (Incyte), in Phase 1 development for vitiligo and FB-102 (Forte Bioscience) in Phase 1b development for celiac disease, and three anti-IL-15 monoclonal antibodies, AMG 714 (Amgen), currently in Phase 2 development for celiac disease, CALY-002 (Novartis), currently in Phase 1b development for celiac disease and eosinophilic esophagitis, and TEV-408 (Teva), currently in Phase 1b development for celiac disease and vitiligo.
• For the anti-BDCA2 program, competitors include another anti-BDCA2 antibody, litifilimab (Biogen) in Phase 3 development for SLE and CLE, and an anti-ILT7 antibody, daxdilimab (Amgen) in Phase 2 development for dermatomyositis or anti-synthetase inflammatory myositis, and discoid lupus erythematosus.

Legal Proceedings

• From time to time, we may be involved in legal proceedings arising in the ordinary course of our business.

Stakeholder Impact

• Positive clinical trial results could benefit shareholders through potential stock price appreciation.
• Successful development and commercialization of product candidates could provide new treatment options for patients with autoimmune and inflammatory diseases.
• The company's collaborations with GSK and Vanda could impact the financial performance and strategic direction of those companies.

Next Steps

• Report top-line data for the rosnilimab Phase 2 trial in ulcerative colitis in the fourth quarter of 2025.
• Initiate enrollment for a Phase 1 clinical trial of ANB101 in the first quarter of 2025.

Key Dates